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Tackling overprescribing
Long overdue with a lot to do
Fraz A Mir, 1 Lindsay Morgan, 2 Elizabeth Houghton3
The UK government recently published its long
awaited review ledby the chief pharmaceutical officer
to evaluate overprescribing in England.1 It revealed
how NHS spending on medicines increased sharply
from £13bn (€15bn; $18bn) in 2010-11 to £18.2bn in
2017-18. Over one billion prescription items were
dispensed in primary care alone, with an estimated
10% being “overprescribed”—that is, not needed or
wantedby the patient, potentiallymore harmful than
beneficial, or having more appropriate alternatives.
The negative consequences for patients are clear: a
fifth of hospital admissions among adults over 65 are
the result of adverse effects of prescribed drugs. But
overprescribinghas substantial environmental impact
too. Currently 25% of the NHS’s carbon footprint
comes frommedicines, and reducing overprescribing
will go some way to achieving a “net zero” NHS.2
A key recommendation of the report is cultural
change to reduce reliance on medicines and to
support prescribing practices based on shared
decision making, reflecting patient values and
preferences informed by the best available evidence
and expertise.3 We live in an era in which there is
virtually “a pill for every ill”: the British National
Formulary contained around 250drugs in 1949; today
it comprises over 18 000. Thus it is more practical,
convenient, andoften cheaper to prescribe drugs (eg,
opiates for chronic back pain) than explore
non-pharmacological interventions such as
physiotherapy.4
Furthermore, clinical “inertia” means that risk from
passive continuationofunnecessarymedicines seems
to be more acceptable than that from active changes
or harm from undertreatment.5 Such attitudes are
reinforced by time pressures on prescribers and
limited awareness and availability of social
prescribing, which improves health and wellbeing
by connecting people to community services.6
Interestingly, the report places limited emphasis on
educating and empowering patients to know more
about their medications or to take ownership of their
therapy. Such patient centred engagement may help
informshareddecisionmaking,manageexpectations,
and improve adherence, which is conspicuously
absent from the report.7 -9
Continuing medicines education for all healthcare
professionals is critical to reducing overprescribing10
but is also missing from the report. Treatment
guidelines for most common medical conditions are
based on high quality evidence. However, these
recommendations are derived from large population
based studies, which can be challenging for even the
most experienced clinician to apply to individuals,
particularly older adults, people with disabilities,
and those with ethnic minority backgrounds, who
are under-represented in trials.11
Teaching on prescribing has been taken seriously in
undergraduate medical curriculums in the UK since
the prescribing safety assessment was introduced in
2014.12 But much more is required to raise awareness
of overprescribing and to develop, evaluate, and
implement effective interventions to tackle it. Equally
pressing is the need for more evidence and guidance
on how best to withdraw inappropriate medication
(deprescribing).13 14 Clinical trials havealready shown
that it is safe and even beneficial for patients to stop
some long term drugs such as antidepressants and
statins towards the end of life.15 16
The new overprescribing review rightly highlights
system-wide changes needed to improve digital
records, increase their accessibility to patients, and
ensure interoperability between care systems. At a
time when general practitioners are struggling to
meet patient needs,17 recommending 30 minute
consultations for structured medication reviews and
greater numbers of clinical pharmacists is welcome
but will require substantial new funding.
The report’s focus is very much on primary care and
community pharmacists, encouraging them to
“challenge” prescribing practice in secondary care.
For example, patients are often prescribed more
medicines ondischarge than theywere onadmission,
and an opportunity to rationalise treatment is
missed.18 This is partly reflected in the alarming cost
of hospital prescribing,whichhas doubled to £11.7bn
a year since 2014.19 Hospital experts in medicines
management andoptimisation suchas senior clinical
pharmacists and pharmacologists have a pivotal role
in reducing overprescribing, including leading
deprescribing initiatives locally and regionally, and
need to be better used .20
Other promising developments given insufficient
attention in the report include point-of-care testing
in the community—to help guide use of antibiotics,
for example 21; use of artificial intelligence to identify
associations between drugs and outcomes and to
developpredictive algorithms to guide individualised
selection andmanagement ofmedicines22 23; and the
potential of pharmacogenomics in “personalised”
and ”precision prescribing” to maximise treatment
benefits and minimise harms.24 25
In addition, legislative and regulatory changes are
required to ensure that priority is given to new drugs
that are clearly better than existing treatments rather
than those that are simply “non-inferior.” Similarly,
a move away from target driven funding of primary
care and towards incentives that encourage
1the bmj | BMJ 2021;375:n2539 | doi: 10.1136/bmj.n2539
EDITORIALS
1 Cambridge University Hospitals NHS
Trust, Cambridge, UK
2 University of East Anglia, Norwich, UK
3 Health Education England, East of
England, UK
Correspondence to: F A Mir
fam31@cam.ac.uk
Cite this as: BMJ 2021;375:n2539
http://dx.doi.org/10.1136/bmj.n2539
Published: 20 October 2021
comprehensive individual medication reviews is overdue.
Overall, this report is welcome and includes several commendable
recommendations. But there remainsmuch todobeforehighquality
individualised prescribing becomes a reality. With a concerted and
collaborative national effort, good leadership, and adequate
funding, it need not be a bitter pill to swallow.
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial
companies. The authors declare the following other interests: FAM is senior medical adviser to the
British National Formulary and chair of its joint formulary committee. Further details of The BMJ policy
on financial interests is here: https://www.bmj.com/sites/default/files/attachments/re-
sources/2016/03/16-current-bmj-education-coi-form.pdf.
Provenance and peer review: Commissioned; not externally peer reviewed.
1 Chief Pharmaceutical Officer. Good for you, good for us, good for everybody—a plan to reduce
overprescribing to make patient care better and safer, support the NHS, and reduce carbon
emissions. 2021. https://www.gov.uk/government/publications/national-overprescribing-review-
report
2 NHS England, NHS Improvement. A net zero NHS. 2020. https://www.england.nhs.uk/green-
ernhs/wp-content/uploads/sites/51/2020/10/delivering-a-net-zero-national-health-service.pdf
3 Jansen J, Naganathan V, Carter SM, etal. Too much medicine in older people? Deprescribing
through shared decision making. BMJ 2016;353:i2893. doi: 10.1136/bmj.i2893 pmid: 27260319
4 O’Sullivan P. It’s time for change with the management of non-specific chronic low back pain. Br
J Sports Med 2012;46:224-7. doi: 10.1136/bjsm.2010.081638 pmid: 21821612
5 Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review.
Adv Ther 2018;35:1735-45. doi: 10.1007/s12325-018-0819-5 pmid: 30374807
6 Roland M, Everington S, Marshall M. Social prescribing—transforming the relationship between
physicians and their patients. N Engl J Med 2020;383:97-9.
doi: 10.1056/NEJMp1917060 pmid: 32640128
7 Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of
deprescribing: a systematic review. Drugs Aging 2013;30:793-807.
doi: 10.1007/s40266-013-0106-8 pmid: 23912674
8 Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a
meta-analysis.MedCare 2009;47:826-34. doi: 10.1097/MLR.0b013e31819a5acc pmid: 19584762
9 Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J. Interventions for improvingmedication-taking
ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst
Rev 2020;5:CD012419.pmid: 32383493
10 Gupta R,Marshall J, Munoz JC, Kottoor R, Jamal MM, Vega KJ. Decreased acid suppression therapy
overuse after education and medication reconciliation. Int J Clin Pract 2013;67:60-5.
doi: 10.1111/ijcp.12046 pmid: 23241049
11 Clark LT, Watkins L, Piña IL, etal. Increasing diversity in clinical trials: overcoming critical barriers.
Curr Probl Cardiol 2019;44:148-72. doi: 10.1016/j.cpcardiol.2018.11.002 pmid: 30545650
12 Prescribing safety assessment. https://prescribingsafetyassessment.ac.uk/
13 Deprescribing. https://deprescribing.org/
14 Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SDS, Roberts HC. A systematic review of the
evidence for deprescribing interventions among older people living with frailty. BMC Geriatr
2021;21:258. doi: 10.1186/s12877-021-02208-8 pmid: 33865310
15 Lewis G, Marston L, Duffy L, etal. Maintenance or discontinuation of antidepressants in primary
care. N Engl J Med 2021;385:1257-67. doi: 10.1056/NEJMoa2106356 pmid: 34587384
16 Kutner JS, Blatchford PJ, Taylor DHJr, etal. Safety and benefit of discontinuing statin therapy in
the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med
2015;175:691-700. doi: 10.1001/jamainternmed.2015.0289 pmid: 25798575
17 Inside a GP surgery: “There is not enough time or space in the day.” BBC News 2021 Sep 4.
https://www.bbc.co.uk/news/uk-england-northamptonshire-58556542
18 Krause O, Glaubitz S, Hager K, Schleef T, Wiese B, Junius-Walker U. Post-discharge adjustment
ofmedication in geriatric patients: a prospective cohort study. Z Gerontol Geriatr 2020;53:663-70.
doi: 10.1007/s00391-019-01601-8 pmid: 31440831
19 NHSDigital. Prescribing costs in hospitals and the community 2019-2020. https://digital.nhs.uk/da-
ta-and-information/publications/statistical/prescribing-costs-in-hospitals-and-the-community
20 Bennett F, Shah N, Offord R, Ferner R, Sofat R. Establishing a service to tackle problematic
polypharmacy. Future Healthc J 2020;7:208-11. doi: 10.7861/fhj.2019-0048 pmid: 33094229
21 Boere TM, van Buul LW, Hopstaken RM, etal. Effect of C reactive protein point-of-care testing
on antibiotic prescribing for lower respiratory tract infections in nursing home residents: cluster
randomised controlled trial. BMJ 2021;374:n2198. doi: 10.1136/bmj.n2198 pmid: 34548288
22 Eggerth A, Hayn D, Schreier G. Medicationmanagement needs information and communications
technology-based approaches, including telehealth and artificial intelligence. Br J Clin Pharmacol
2020;86:2000-7. doi: 10.1111/bcp.14045 pmid: 31271668
23 Sirois C, Khoury R, Durand A, etal. Exploring polypharmacywith artificial intelligence: data analysis
protocol. BMC Med Inform Decis Mak 2021;21:219.
doi: 10.1186/s12911-021-01583-x pmid: 34284765
24 Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;526:343-50.
doi: 10.1038/nature15817 pmid: 26469045
25 Kim K, Magness JW, Nelson R, Baron V, Brixner DI. Clinical utility of pharmacogenetic testing
and a clinical decision support tool to enhance the identification of drug therapy problems through
medication therapy management in polypharmacy patients. J Manag Care Spec Pharm
2018;24:1250-9. doi: 10.18553/jmcp.2018.24.12.1250 pmid: 30479202
the bmj | BMJ 2021;375:n2539 | doi: 10.1136/bmj.n25392
EDITORIALS
